The psychedelic landscape is changing rapidly. Several states have decriminalized their use, research and development on potential benefits and medical therapies are expanding, and companies are engaging in the manufacturing and synthesis of psychedelics.
As this emerging sector gains momentum, many entrepreneurs and even large biotech companies are raising capital and laying the groundwork to capitalize on a new market in anticipation of potential medical use approval from the FDA or even an adult-use recreational market someday.
However, the psychedelics industry is rife with complex legal and regulatory requirements given that, like cannabis, psychedelics are still illegal under federal law and state laws involving their manufacture, sale and consumption vary widely.
Fortis Law Partners is on the leading edge of this industry as one of a limited number of U.S. firms with an in-house psychedelics practice group. We bring the decades-long expertise and foundational knowledge of our sophisticated cannabis team to our psychedelics practice.
Our attorneys assist clients ranging from those directly involved in the psychedelics industry to businesses affiliated with the operations and infrastructure of the psychedelics industry to investors in the psychedelics industry.
The Fortis team can help psychedelic companies with a wide range of affairs, including:
The type of corporate formation and tax structures that are most appropriate to the psychedelics sector
Establishing a best-in-class supply chain and operational and cGMP manufacturing protocols
Raising investor capital
Protecting intellectual property
Navigating myriad and complex FDA and healthcare regulations
International trade and import/exports
Product claims and marketing compliance
Clients can rely on Fortis to expertly guide them through this evolving space. Contact us today for more information or to arrange a consultation.